BMO Capital Starts Blueprint Medicines (BPMC) at Market Perform

BMO Capital analyst George Farmer initiates coverage on Blueprint Medicines (NASDAQ: BPMC) with a Market Perform rating and a price target of $74.00.

The analyst commented, "We launch coverage of Blueprint Medicines at Market Perform with a $74 target price. While we see significant market opportunities for lead assets avapritinib for genetically defined solid tumors and systemic mastocytosis, and pralsetinib for treatment of RET+ solid tumor indications, we remain on the sidelines and recommend investment at a more attractive entry point."

For an analyst ratings summary and ratings history on Blueprint Medicines click here. For more ratings news on Blueprint Medicines click here.

Shares of Blueprint Medicines closed at $65.58 yesterday.

You May Also Be Interested In

• BofA Securities Resumes American Eagle Outfitters (AEO) at Underperform
• Piper Sandler Reiterates Overweight Rating on Estee Lauder (EL), 'F4Q26 Preview'
• BMO Capital Reiterates Outperform Rating on Netflix (NFLX), Advertising Seen As a Key Lever